Abstract
This study characterizes the molecular defect causing androgen resistance in two 46,XY siblings with complete testicular feminization. While hormone binding studies in genital skin fibroblasts showed residual activity, no immunoreactive androgen receptor (AR) was detected using anti-NH2-terminal antibodies, suggesting an abnormal amino terminus. Genetic analysis revealed a point mutation (CAG $\rightarrow$ TAG, Gln60 $\rightarrow$ Stop) at nucleotide 340. In vitro studies demonstrate that AR synthesis is re-initiated downstream of this stop codon, resulting in a truncated protein produced at low levels with significantly impaired function. This novel mechanism highlights the vital role of the amino-terminus in AR function and enabled successful prenatal diagnosis in the affected family.
Introduction
Androgen Insensitivity Syndrome (AIS), or testicular feminization, occurs when individuals with a 46,XY genotype are resistant to male sex hormones, resulting in a female physical phenotype. While many cases are linked to mutations in the hormone-binding or DNA-binding domains, the role of the amino-terminus—the front end of the protein—has been less clearly defined. This research investigates two siblings with complete androgen resistance to understand how a mutation in this specific region completely disrupts receptor function, even when the hormone-binding domain remains largely intact.
Methods
The research team employed a multi-faceted approach to identify the molecular basis of the disorder:
- Fibroblast Binding Studies: Cultured skin cells from patients were used to measure the binding capacity ($B_{max}$) and dissociation rates of dihydrotestosterone (DHT).
- Genetic Sequencing: The AR gene was amplified and sequenced to identify the specific mutation.
- Functional Expression: Site-directed mutagenesis recreated the mutation in vitro. These mutant genes were expressed in various cell lines (CHO, CV1, and COS) to observe protein production and transcriptional activation of reporter genes.
- Immunoblotting: Specific antibodies were used to determine the size and quantity of the resulting receptor proteins.
Key Insights: Downstream Initiation and Functional Impairment
The identified mutation (Q60X) changes a glutamine codon into a "Stop" signal early in the gene. Typically, such a mutation prevents the production of any functional protein. However, the study found that the cell's translation machinery "re-initiated" synthesis at a downstream site, specifically at Methionine 188.
This "downstream initiation" produced a truncated 87-kD protein, compared to the normal 110-kD receptor. This mechanism causes androgen resistance through a "double whammy":
- Reduced Quantity: Downstream initiation is highly inefficient, leading to approximately 100-fold lower levels of the receptor protein.
- Reduced Quality: The truncated molecules are functionally impaired, possessing only a fraction of the normal transcriptional activity. At equivalent expression levels, the mutant showed only ~8% of normal activity.
Results and Clinical Application
In cell assays, the mutant receptor required much higher concentrations of DNA to produce even a weak signal. Even when "overexpressed" in the laboratory, its activity reached only ~30% of the normal maximum.
Crucially, identifying this mutation allowed the team to perform a successful prenatal diagnosis for a third sibling. They confirmed that the 46,XY fetus did not carry the mutation at 9 weeks gestation, providing vital information for the family's clinical management.
Conclusion
These results define a novel mechanism for androgen resistance: the combination of decreased protein amount and functional impairment caused by an abnormality within the amino terminus of the receptor. The findings suggest that domains critical for the in vivo function of the receptor reside within the amino terminus, and their disruption can lead to complete resistance even with relatively subtle effects on hormone binding.
Summary updated